- Location
Forest Laboratories
"-
Trevena Announced Today Initiation of Dosing in BLAST-AHF
Jan 10, 2014Trevena, Inc., a clinical stage pharmaceutical company involved in the discovery and development of G-protein coupled receptor (GPCR) biased ligands, announced today initiation of dosing in BLAST-AHF, the Company's randomized, multi-center ...
Tags: Trevena, GPCR biased ligands, BLAST-AHF, acute heart failure
-
Forest Laboratories Has Entered Into a Definitive Agreement to Acquire Aptalis
Jan 9, 2014Forest Laboratories, Inc. (NYSE:FRX) today announced that it has entered into a definitive agreement to acquire Aptalis, a privately held U.S. based specialty Gastrointestinal (GI) and Cystic Fibrosis company, for $2.9 billion in cash from ...
Tags: Forest Laboratories, definitive agreement, acquisition, Aptalis
-
FRX Has Received QIDP Designation for Its Ceftazidime/Avibactam Drug From FDA
Sep 17, 2013US-based pharmaceutical manufacturer and marketer Forest Laboratories (FRX) has received qualified infectious disease product (QIDP) designation for its ceftazidime/avibactam drug from the US Food and Drug Administration (FDA). Currently ...
Tags: drug, Forest Laboratories
-
Innopharma Has Introduced Acamprosate Calcium The Generic Version of Campral
Aug 19, 2013Sterile product development company InnoPharma has introduced acamprosate calcium, 333mg delayed-release tablets, the generic version of Campral. The generic formulation of acamprosate delayed-release tablets was developed by InnoPharma, ...
Tags: Generic Version, Campral
-
Amerigen Collaborated to Develop a Number of Specialty Generic Products
Aug 2, 2013Amerigen Pharmaceuticals, a group of companies engaged in all phases of the generic pharmaceutical business, has collaborated with Forest Laboratories to develop a number of specialty generic products. The collaboration will leverage ...
Tags: Amerigen Partners, Generic Product
-
Forest Laboratories and Almirall Have Reported Positive Results From The Aclidinium
May 3, 2013Forest Laboratories and Almirall have reported positive results from the ACLIdinium/FORMoterol fumarate combination for Investigative use in the treatment of moderate to severe COPD (ACLIFORM/COPD) Phase III study. ACLIFORM/COPD is the ...
-
Health Canada Issued a Notice of Compliance for Forest Laboratories Hypertension Therapy
Jan 21, 2013Health Canada has issued a notice of compliance for Forest Laboratories Canada's hypertension therapy, Bystolic (nebivolol) tablets. The company anticipates making the hypertension medication, that is to be administered once a day, ...
-
Ironwood Pharmaceuticals and Forest Laboratories Have Announced The Availability of GC-C
Dec 20, 2012Ironwood Pharmaceuticals and Forest Laboratories have announced the availability of guanylate cyclase-C (GC-C) agonist, Linzess across the US pharmacies. The FDA approved, once-daily, oral product is indicated for adults with irritable ...
Tags: FDA, CIC, Ironwood Pharmaceuticals and Forest Laboratories, Medicine
-
The FDA Approved Long-Acting Anticholinergic Was Indicated
Dec 14, 2012Forest Laboratories and Almirall have announced the commercial availability of anticholinergic agent Tudorza Pressair in 400mcg dose strength, in the US pharmacies. The FDA approved long-acting anticholinergic was indicated for the ...
Tags: anticholinergic agent, pharmacies, multidose, Almirall, medicine
-
Forest Laboratories and Adamas Pharmaceuticals Collaborated for The Development of FDC
Nov 28, 2012Forest Laboratories and Adamas Pharmaceuticals have collaborated for the development of a fixed dosed combination (FDC) of Namenda XR and donepezil HCl for Alzheimer's dementia in the US. The company expects to launch the FDC that will be ...
